RTA 402
( DrugBank: - / KEGG DRUG: - )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 67 | Polycystic kidney disease | 9 |
| 86 | Pulmonary arterial hypertension | 6 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 218 | Alport syndrome | 4 |
67. Polycystic kidney disease
Clinical trials : 233 / Drugs : 188 - (DrugBank : 54) / Drug target genes : 60 - Drug target pathways : 165
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
86. Pulmonary arterial hypertension
Clinical trials : 1,288 / Drugs : 565 - (DrugBank : 126) / Drug target genes : 81 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
218. Alport syndrome
Clinical trials : 41 / Drugs : 32 - (DrugBank : 19) / Drug target genes : 8 - Drug target pathways : 44
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|